Tokai, JHU Ink CDx Deal for Castration-resistant Prostate Cancer Rx Development | GenomeWeb

NEW YORK (GenomeWeb) – Tokai Pharmaceuticals said today it is working with Johns Hopkins University to develop a companion diagnostic for its investigational, castration-resistant prostate cancer (CRPC) drug galeterone.

Under its agreement, Cambridge, Mass.-based Tokai has garnered an exclusive, worldwide license from JHU for "patent applications and know-how" covering a test used to assess the AR-V7 status of prostate cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.